Objective: To explore the effects of Danqi Yishen Capsule (Danqi Capsule for Tonifying
Kidney) on blood lipid levels and hemorheological indicators of hyperlipidemia patients. Methods:A total of 96 patients with hyperlipidemia were randomly divided into the control group and observation group of 48 cases respectively.
The control group was given by simvastatin in oral administration of 10 mg half
an hour after dinner, once a day, while the observation group based on the treatment
of the control group, was orally given Danshen Yishen Capsule of three capsules each
time, three times a day. The treatment of both groups lasted for two months. Then
the comparison focused on blood lipid levels, hemorheological indicators, and adverse reactions between
both groups before and after the treatment. Results:There was
no significant difference in blood lipid levels and hemorheological indicators
between both groups before the treatment (P> 0.05). The symptoms of
both groups were significantly improved after the treatment, and the difference
before and after the treatment was statistically significant (P< 0.05), and the difference between both groups was
also statistically significant
References
[1]
Liu, X.J., Chen, C.F. and Liu, S.H. (2017) Clinical Observation of Coronary Heart Disease with Qi-Yin Deficiency and Blood Stasis Syndrome by Using Shengmai Powder Combined with Xuefu Zhuyu Decoction. Journal of Hunan University of Chinese Medicine, 37, 423-425.
[2]
Wang, B. (2016) Effects of Xuefu Zhuyu Decoction on Prostacyclin and Thromboxane A2 in Blood Lipid and Plasma of Atherosclerosis Rats. Journal of Community Medicine, 14, 57-58.
[3]
Ma, L.Y. (2018) Research Progress on Related Adverse Reactions and Non-Cardiovascular Effects of Statins. Guide of China Medicine, 16, 8-9.
[4]
Zhu, J.R., Gao, R.L., Zhao, S.P., et al. (2017) 2016 Chinese Guideline for the Management of Dyslipidemia in Adults. Chinese Journal of Health Management, 11, 7-28.
[5]
Zheng, X.Y. (2002) Guiding Principles for Clinical Research on Novel Chinese Materia Medica. China Medical Science Press, Beijing, 85-89.
[6]
Zhang, S.H., Wei, G. and Xu, J.W. (2019) To Explore the Clinical Efficacy and Safety of Different Doses of Simvastain Treatment of Elderly Hypertension Combined Hyperlipidemia. Journal of Frontiers of Medicine, 9, 112-113.
[7]
Yu, X.M., Yang, G.H. and Li, P. (2014) Mechanism of Lowering Blood Lipids of Xuefuzhuyu Decoction in Patients with Hyperlipidemia. Liaoning Journal of Traditional Chinese Medicine, 41, 289-291.
[8]
Wu, X., Zhu, B., Li, W.X., et al. (2013) Effect of Xuefu Zhuyu Decoction on Serum Adiponectin Level in Hyperlipidemia SD Rats. Progress in Veterinary Medicine, 34, 76-79.
[9]
Song, X. (2008) Physiological Characteristics of the Elderly in Traditional Chinese Medicine. Journal of Chengdu University of Traditional Chinese Medicine, 31, 13-16.
[10]
Cui, L.L. (2012) The Damage of Hyperlipidemia and Its Prevention with TCM. Western Journal of Traditional Chinese Medicine, 25, 101-102.
[11]
Ye, Q. and Gu, Y.H. (2014) Introduction of Chinese Medicine Treatment of Hyperlipemia. Journal of Liaoning University of Traditional Chinese Medicine, 16, 159-160.
[12]
Yili, G. (2016) Research Progress of Traditional Chinese Medicine on Hyperlipidemia. Guangming Journal of Chinese Medicine, 31, 444-447.
[13]
Gong, Y.P. and Song, G.P. (2001) Correlations between Dysfunctions of Zang-Fu Organs and Hyperlipidemia. Chinese Journal of Information on Traditional Chinese Medicine, 8, 7-8.
[14]
Li, T. and Zhao, Y.Q. (2013) Discussion on Hyperlipidemia Based on the Perspective of Kidney Blood. Clinical Journal of Chinese Medicine, 5, 58-59.
[15]
Ford, E.S., Giles, W.H. and Dietz, W.H. (2002) Prevalence of the Metabolic Syndrome among US Adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA, 287, 356-359. https://doi.org/10.1001/jama.287.3.356
[16]
Xu, Y.F., Liu, J. and Li, Z.H. (2011) Professor LI Zhen-Hua’s Experience in Treating Obesity. China Journal of Traditional Chinese Medicine and Pharmacy, 26, 1542-1543.
[17]
Chen, Q.G., Dai, Z.Q., Tao, F., et al. (2016) Ding Xueping’s Clinical Experience in Treating Obesity. Shanghai Journal of Traditional Chinese Medicine, 50, 17-19.
[18]
Xu, S.S., Gong, M.R. and Sun, Y.N. (2015) Simple Obesity Treatment from Spleen and Stomach. Liaoning Journal of Traditional Chinese Medicine, 42, 628-629.
[19]
Feng, X.R. (2007) Analysis on “Kidney Is the Resource of Phlegm”. Lishizhen Medicine and Materia Medica Research, 18, 979．
[20]
Wang, A.L., Xu, H. (2015) Professor Xu Hao’s Clinical Experience in Treating Hyperlipidemia Based on Constitution Differentiation from Liver, Spleen and Kidney. China Journal of Traditional Chinese Medicine and Pharmacy, 30, 1999-2001.
[21]
Zhang, J.M., La, W.Y. (2008) Research Progress of the Treatment of Traditional Chinese Medicine on Hyperlipidemia of Type 2 Diabetes. Hebei Journal of Traditional Chinese Medicine, 30, 214-216.
[22]
Yang, F., Huang, J.R. and Xiang, N. (2009) Relations between Dysfunctions of Liver and Spleen and Insulin Resistance. Lishizhen Medicine and Materia Medica Research, 20, 1556-1557.
[23]
Ren, J.X. (2003) Exploration on Latent Pathogens II: Miscellaneous Diseases. Chinese Medicine Modern Distance Education of China, 1, 8．
[24]
Mou, Z.Y. (2015) Correlations between Acute Coronary Syndrome and Latent Pathogens in Phlegm and Stasis. Chinese Journal of Gerontology, 35, 294-296．
[25]
Chen, W.K. (1988) Prevention and Treatment of Traditional Chinese Medicine on Hyperlipidemia. Traditional Chinese Medicine Ancient Books Publishing House, Beijing, 13.
[26]
Li, M.Q., Lin, Y., Xiang, L., et al. (2019) Dan-Zhuo and Glucolipid Metabolic Disorders. World Chinese Medicine, 14, 652-655.
[27]
He, W., Xing, Y.R., Zhang, J.M., et al. (2013) Analysis and Summary of Modern TCM Turbid Pathogenic Factor Theory. Shaanxi University of ChinesAe Medicine, 36, 13-16．
[28]
Yin, F., Chen, X.Z. and Yang, L. (2006) Pattern Differentiation and Treatment on Hyperlipidemia Based on Kidney Deficiency and Blood Stasis. Journal of Sichuan of Traditional Chinese Medicine, 24, 25-26.
[29]
Du, S., Hu, J.Q., Lu, H.R. (2015) Review on Modern Theoretical Research Progress of Syndrome of Intermingled Phlegm and Blood Stasis. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, No. 4, 477-482.
[30]
Tian, Y., Xu, Y., Xia, L.N., et al. (2014) Effects of Shenqi Compound on Serum IL-6 and Blood Lipid in High-fat Feeding GK Rats. Forum on Traditional Chinese Medicine, 29, 43-44.
[31]
Xu, H. (2017) The Effect of Compound Danshen Dripping Pills and Shenqiyiqi Dripping Pills on Cardiovascular Diseases. Shandong University, Jinan.
[32]
Zhao, X.J. (2018) Effect Observation of Shenqi Compound Combined with Vildagliptin on Diabetic Macrovascular Complications. Modern Journal of Integrated Traditional Chinese and Western Medicine, 27, 2804-2807.
[33]
Yan, J. and Jia, H.L. (2019) Effects of Xuefu Zhuyu Decoction on Blood Lipid Levels and Hemorheological Indicators of the Patients with Hyperlipemia. Western Journal of Traditional Chinese Medicine, 32, 47-49.
[34]
Liu, D.W. (2018) Regulation of Danqi Yishen Capsule on Diabetic Nephropathy and Laboratory Indicators. Chinese Journal of Primary Medicine and Pharmacy, 25, 3141-3144.
[35]
Li, L. and Wang, T. (2020) Absorbed Components of Jinqi Jiangtang Formula and Its Effects on Lipid Accumulation of HepG2 Cells. Chinese Remedies & Clinics, 20, 356-358.
